PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PTCT | PTC THERAPEUTICS, INC. | 2026-03-03 12:07:16 | 64.18 | -2.19 | -3.3 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTCT | 0001070081 | PTC THERAPEUTICS, INC. | US69366J2006 | 549300UJLWOIWFDGB318 | 043416587 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 500 WARREN CORPORATE CENTER DRIVE | WARREN | NJ | 07059 | UNITED STATES | US | 9082227000 | 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 | 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059 | PTC THERAPEUTICS INC | Pharmaceuticals | 1998-01-01 | — | — | https://ptcbio.com | 3,350,589 | 81,474,366 | 82,774,730 | PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control (PTC) mechanisms in orphan diseases. | 2026-02-26 16:35:55 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 3,350,589 | -1,730,339,485 | -99.8067 | 82,774,730 | 3,905,362 | 4.9517 |
| 2024 | 1,733,690,074 | -596,926,441 | -25.6124 | 78,869,368 | 2,261,338 | 2.9518 |
| 2023 | 2,330,616,515 | 201,084,121 | 9.4426 | 76,608,030 | 2,792,886 | 3.7836 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Eric Pauwels | Chief Business Officer | 2024 | 570,217 | 0 | 624,267 | 436,900 | 25,056 | 2,398,470 |
| Lee Golden | Chief Medical Officer, Executive Vice President | 2024 | 548,333 | 0 | 580,594 | 421,000 | 23,538 | 2,248,039 |
| Matthew B. Klein | Chief Executive Officer | 2024 | 882,167 | 0 | 2,998,300 | 1,149,700 | 19,591 | 7,410,765 |
| Pierre Gravier | Chief Financial Officer | 2024 | 542,500 | 0 | 567,749 | 455,200 | 21,360 | 2,227,654 |
| Lee Golden | Chief Medical Officer, Executive Vice President | 2023 | 507,917 | 0 | 863,369 | 189,000 | 19,868 | 2,394,995 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 991 |
| 2024 | 939 |
| 2023 | 995 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 1,730,655,000 | 806,780,000 | 937,822,000 |
| Cost Of Revenue | — | 57,398,000 | 65,486,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 455,249,000 | 534,480,000 | 666,563,000 |
| General And Administrative Expenses | 347,143,000 | 300,911,000 | 332,540,000 |
| Operating Expenses | 863,720,000 | 1,109,350,000 | 1,377,324,000 |
| Operating Income | 866,935,000 | -302,570,000 | -439,502,000 |
| Net Income | 682,644,000 | -363,295,000 | -626,604,000 |
| Earnings Per Share Basic | 8.58 | -4.73 | -8.37 |
| Earnings Per Share Diluted | 7.78 | -4.73 | -8.37 |
| Weighted Average Shares Outstanding Basic | 79,534,290 | 76,845,055 | 74,838,392 |
| Weighted Average Shares Outstanding Diluted | 88,311,494 | 76,845,055 | 74,838,392 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 984,648,000 | 779,709,000 | 594,001,000 |
| Marketable Securities Current | 960,723,000 | 359,987,000 | 282,738,000 |
| Accounts Receivable | 181,621,000 | 158,554,000 | 160,822,000 |
| Inventories | 79,647,000 | 23,194,000 | 30,577,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 2,273,948,000 | 1,365,531,000 | 1,218,629,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 55,371,000 | 60,970,000 | 87,089,000 |
| Other Assets Non Current | 0 | 0 | 235,766,000 |
| Total Assets Non Current | 624,819,000 | 339,493,000 | 677,069,000 |
| Total Assets | 2,898,767,000 | 1,705,024,000 | 1,895,698,000 |
| Accounts Payable | 45,487,000 | 17,274,000 | 6,045,000 |
| Deferred Revenue | 2,040,000 | 5,505,000 | 801,000 |
| Short Term Debt | 286,631,000 | — | — |
| Other Liabilities Current | 4,677,000 | 4,701,000 | — |
| Total Liabilities Current | 968,427,000 | 580,981,000 | 603,100,000 |
| Long Term Debt | 286,631,000 | 285,412,000 | 284,213,000 |
| Other Liabilities Non Current | 13,704,000 | 21,426,000 | 141,000 |
| Total Liabilities Non Current | 2,135,653,000 | 2,222,114,000 | 2,111,153,000 |
| Total Liabilities | 3,104,080,000 | 2,803,095,000 | 2,714,253,000 |
| Common Stock | 80,000 | 77,000 | 75,000 |
| Retained Earnings | -2,964,229,000 | -3,646,873,000 | -3,283,578,000 |
| Accumulated Other Comprehensive Income | 10,501,000 | -25,886,000 | -1,285,000 |
| Total Shareholders Equity | -205,313,000 | -1,098,071,000 | -818,555,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 38,815,000 | 75,663,000 | 236,590,000 |
| Share Based Compensation Expense | 74,547,000 | 74,615,000 | 101,636,000 |
| Other Non Cash Income Expense | -130,000 | -4,298,000 | — |
| Change In Accounts Receivable | 10,151,000 | -1,732,000 | 1,539,000 |
| Change In Inventories | 53,896,000 | -6,164,000 | 8,183,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 71,741,000 | -33,322,000 | 48,346,000 |
| Change In Other Liabilities | -17,396,000 | 11,830,000 | -2,307,000 |
| Cash From Operating Activities | 711,196,000 | -107,688,000 | -158,418,000 |
| Purchases Of Marketable Securities | 53,628,000 | 59,377,000 | 38,398,000 |
| Sales Of Marketable Securities | 783,896,000 | 549,609,000 | 21,544,000 |
| Acquisition Of Property Plant And Equipment | 8,860,000 | 6,502,000 | 28,438,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -861,984,000 | 44,182,000 | -176,737,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 5,944,000 | 5,199,000 | 5,954,000 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 331,094,000 | 255,866,000 | 646,400,000 |
| Change In Cash | 203,018,000 | 185,032,000 | 314,359,000 |
| Cash At End Of Period | 984,648,000 | 779,709,000 | 594,001,000 |
| Income Taxes Paid | 36,854,000 | 17,550,000 | 14,155,000 |
| Interest Paid | 5,702,000 | 5,823,000 | 36,131,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 8.58 | -4.73 | -8.37 |
| Price To Earnings Ratio | 8.8531 | -9.5433 | -3.2927 |
| Earnings Growth Rate | -281.3953 | -43.4886 | 7.4454 |
| Price Earnings To Growth Ratio | -0.0315 | 0.2194 | -0.4422 |
| Book Value Per Share | -2.5814 | -14.2894 | -10.9376 |
| Price To Book Ratio | -29.4254 | -3.159 | -2.5197 |
| Ebitda | 763,845,000 | -264,565,000 | -344,959,000 |
| Enterprise Value | 5,630,038,668.4 | 2,974,488,782.7 | 1,752,758,083.52 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -2.7921 | -0.2599 | -0.3472 |
| Capital Expenditures | 33,216,000 | 49,544,000 | 251,089,000 |
| Free Cash Flow | 677,980,000 | -157,232,000 | -409,507,000 |
| Return On Equity | -3.3249 | 0.3308 | 0.7655 |
| One Year Beta | 0.9375 | 1.3718 | 1.3462 |
| Three Year Beta | 1.1272 | 1.0338 | 0.9075 |
| Five Year Beta | 0.9644 | 0.992 | 0.9989 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Boulding Mark Elliott | EXEC. VP AND CLO | 2026-02-19 | 588 | D | 107,643 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2026-02-19 | 1,629 | D | 106,014 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2026-02-19 | 212 | D | 105,802 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2026-02-19 | 590 | D | 105,212 |
| Boulding Mark Elliott | EXEC. VP AND CLO | 2026-02-18 | 3,081 | D | 108,231 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Pacer Advisors, Inc. | 2025-12-31 | 17,900,202 | 235,653 | 75.96 |
| Invesco Ltd. | 2025-12-31 | 32,988,290 | 434,285 | 75.96 |
| Empowered Funds, LLC | 2025-12-31 | 19,021,296 | 250,412 | 75.96 |
| State of Tennessee, Department of Treasury | 2025-12-31 | 2,464,847 | 32,634 | 75.53 |
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 18,014,586 | 236,909 | 76.0401 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| LAZARD FUNDS INC | 2025-12-31 | Open Shares | LEOOX | 843,040 | -219,867.87 | -0.3647 |
| LAZARD FUNDS INC | 2025-12-31 | Institutional Shares | LEOIX | 843,040 | -219,867.87 | -0.3647 |
| PIMCO Equity Series | 2025-12-31 | PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETF | MFUS | 285 | 21,648.6 | 0.0103 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCFX | 14,278 | 1,084,556.88 | 0.995 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYBOX | 14,278 | 1,084,556.88 | 0.995 |